^
    Back
    Association details:
    Biomarker:OLR1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy

    Published date:
    04/20/2021
    Excerpt:
    In immunotherapy prediction analysis with the comparatively reliable tool TIDE, patients with higher OLR1 expression were predicted to have better immunotherapy outcomes…
    DOI:
    10.3389/fonc.2021.629333